Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7467639
Reference Type
Journal Article
Subtype
Review
Title
[Capecitabine]
Author(s)
Yamaguchi, K; Shimamura, T; Tada, M
Year
2006
Is Peer Reviewed?
Yes
Journal
Gan To Kagaku Ryoho
ISSN:
0385-0684
Volume
33
Issue
7
Page Numbers
891-895
Language
Japanese
PMID
16835474
Abstract
Capecitabine, an oral fluoropyrimidine carbamate, is adopted worldwide. As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV. In a large phase III trial (Xeloda Adjuvant Chemotherapy Trial: X-ACT), as the adjuvant treatment of patients with resected stage III colon cancer, capecitabine showed at least comparable disease-free survival, overall survival, and relapse-free survival with a favorable safety profile to bolus 5-FU/LV. Additionally, capecitabine-based combination regimens with oxaliplatin or irinotecan are now under evaluation. In phase II studies, capecitabine has shown the promising results in combination therapy. In Japan, capecitabine has been evaluated since 1994. In a recent phase II study, which evaluated the global dose as first-line treatment for metastatic colorectal cancer, the response rate was 35% (95% CI 23.1-48.4). The median time to disease progression was 169 days and the median overall survival was 617 days. Hand-foot syndrome (HFS), a characteristic adverse event of capecitabine, was observed in 73.3% of the patients, but the grade 3/4 was observed in 13.3% of the patients and only one patient discontinued the treatment due to HFS. An immediate approval of capecitabine in Japan is expected.
Keywords
antineoplastic agent; antineoplastic antimetabolite; capecitabine; deoxycytidine; drug derivative; fluorouracil; folinic acid; colorectal tumor; disease free survival; drug administration; human; mortality; neoplasm; phase 1 clinical trial; phase 2 clinical trial; review; survival rate; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I; Clinical Trials, Phase II; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Neoplasms; Survival Rate
Tags
Other
•
Harmful Algal Blooms- Health Effects
April 2021 Literature Search
PubMed
Scopus
Saxitoxins
PubMed
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity